Moneycontrol Bureau
Shares of Wockhardt rose over 11 percent intraday on Wednesday. According to CNBC-TV18 sources, US Food and Drug Administration (FDA) has completed inspection of the drug manufacture’s Waluj facility yesterday. The regulator had inspected Wockhardt's Chikalthana facility a month ago.
Meanwhile earlier in April, the Wockhardt has recalled select drugs in the US, manufactured at its two units at Chikalthana and Waluj in Maharashtra, which were under import restrictions from the USFDA.
Wockhardt's L1 Chikalthana facility was under import alert for its drug Metoprolol XR used for treating blood pressure, while the Waluj facility that makes injectables and solid dosages was also put under import restrictions by the US Food and Drug Administration (USFDA) in 2013.
Wockhardt had also said that the UK's health regulator, Medicines and Healthcare products Regulatory Agency (MHRA) has restored the EU GMP certification of the company's potent product facility at Kadaiya, Daman.
At 12:43 hrs Wockhardt was quoting at Rs 1,544.00, up Rs 120.75, or 8.48 percent on the BSE.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
